DEBRA Research GmbH and Dermaliq Therapeutics, Inc. have announced a strategic, non-exclusive collaboration to improve drug delivery for people with Epidermolysis Bullosa (EB), a rare genetic skin disorder. The partnership will initially focus on developing better wound-healing and anti-itch treatments, as well as preventive therapies for EB patients. Alongside this agreement, DEBRA Research has also made a strategic investment in Dermaliq.
EB is a group of rare, painful genetic conditions that cause the skin to be extremely fragile. Even minor friction or trauma can lead to blisters and wounds. This condition greatly impacts the daily lives of those affected and can lead to serious health problems over time, including chronic wounds, infections, and damage to internal organs. EB results from mutations in genes that produce proteins essential for keeping the skin’s structure intact. Although there is no cure yet, new treatments are being developed to ease symptoms, reduce pain, and improve quality of life.
Dermaliq aims to change how skin and wound care are managed for EB patients. Using its proprietary hyliQ® technology, the company can deliver active drugs directly into the skin without physically disturbing fragile or wounded tissue. This touchless method is designed especially for conditions like EB, where even slight friction can cause skin damage. This innovative approach provides important benefits by allowing effective treatment while protecting the delicate skin of patients.
Related Topics:
